IL22 and myeloid sarcoma: Jin Z et al. (Zhen et al., 2017) suggested that IL-22 is involved in inhibiting the function of Tregs cells in MS patients, thereby indirectly promoting the activation and proliferation of effector T cells and promoting the development of the disease.